Some compensation payments for Ozempic vision loss claims are being made in Europe, according to recent news reports.
From this November 21, 2025, article, “Denmark Compensates Four Over Vision Loss Linked To Ozempic, Wegovy“, published by the Agence France Presse (AFP):
Four people in Denmark who developed serious eye conditions after using popular weight-loss and diabetes drugs Wegovy and Ozempic are entitled to compensation, an independent body ruled Friday.
More than 40 people had sought reimbursement after they said they had developed a serious eye condition as a result of using one of the drugs, both made by Novo Nordisk, according to the Danish Patient Compensation association.
The condition — NAION (non-arteritic anterior ischemic optic neuropathy) — is a lack of blood supply to the optic nerve, which can lead to a loss of vision.
The association said that it had ruled on five cases so far, and found four people who merited compensation….
In Denmark, health authorities generally pay out medical compensation for a drug injury such as NAION linked to Ozempic. The Danish Patient Compensation association is an independent body that evaluates these types of patient claims on behalf of the government.
Over the past year, we have heard from people with Ozempic vision loss claims who are seeking compensation payments. In the US, those claims would be filed as drug injury lawsuits in the court system. When successful, the resulting legal compensation payments would be made by the responsible drug company, Novo Nordisk.
Among the liability allegations that would be asserted in the lawsuits for those US Ozempic vision loss claims is Novo Nordisk’s failure to warn that semaglutide has been linked to an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) in several medical studies. The current Ozempic drug label in the US does not have any warnings about NAION.
We are investigating Ozempic vision loss claims for patients who have been diagnosed with NAION, as well as similar cases with the use of Wegovy or Rybelsus, which are two other semaglutide-containing drugs from Novo Nordisk.
Again, these drug injury lawsuits with vision loss claims involving Ozempic, Wegovy, and Rybelsus would be filed against Novo Nordisk for its failure to warn about the increased risk of NAION associated with semaglutide in its current US drug labels for those semaglutide-containing drugs.
If you are interested, you can submit an online Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form. Attorney Tom Lamb reviews each one of these submissions. He evaluates them as possible drug injury lawsuits seeking compensation payments for the person suffering from a loss of vision or blindness due to NAION. This case evaluation service is free and confidential, and without obligation.
[Read the article in full at Drug Injury Watch]Ozempic / Rybelsus / Wegovy
Free Case Evaluation
Strictly Confidential, No Obligation